Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroendocrine Tumors 4von Hippel-Lindau Disease 2Prostatic Neoplasms 2Meningioma 2Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Multiple Endocrine Neoplasia 1Medulloblastoma 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1Hypercalcemia 1Cancer Diagnosis 1Breast Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × gallium Ga 68 dotatate × Clear all
NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡